- Home
- OMER
OMER
Omeros Corporation
as 04-23-2025 4:00pm EST
| Founded: | 1994 | Country: | United States |
| Employees: | N/A | City: | SEATTLE |
| Market Cap: | N/A | IPO Year: | 2009 |
| Target Price: | $22.50 | AVG Volume (30 days): | 917.5K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.70 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.97 - $13.60 | Next Earning Date: | 05-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 2447.88% |
Latest Omeros Corporation News
OMER Breaking Stock News: Dive into OMER Ticker-Specific Updates for Smart Investing
Business Wire
14 days ago
Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros’ Proprietary OncotoX-AML Clinical Program
Business Wire
16 days ago
Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases
Thomson Reuters StreetEvents
23 days ago
Q4 2024 Omeros Corp Earnings Call
GuruFocus.com
23 days ago
Omeros Corp (OMER) Q4 2024 Earnings Call Highlights: Navigating Financial Challenges with ...
Associated Press Finance
24 days ago
Omeros: Q4 Earnings Snapshot
Business Wire
24 days ago
Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results
Business Wire
a month ago
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025
Clinical Trials Arena
a month ago
Omeros to activate site for Phase III programme of zaltenibart for PNH
Compare OMER vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OMER Omeros Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.